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Background. Carcinoma ex-pleomorphic adenoma (CXPA) is a malignant salivary gland tumor that arises rarely in the minor
salivary glands. Although the etiology of CXPA remains unclear, the role of some tumor suppressor genes and oncogenes in
CXPA is documented; however, other genes still need to be studied.
Study design and objective. An uncommon case of CXPA involving the upper lip is presented, which was analyzed by a panel
of tumor suppressor genes by multiplex ligation-dependent probe amplification.
Results. The genes investigated in this study, a loss of copy number was detected for CASP8, CD44, CDH1, DAPK1, ESR1,
RASSF1, and TP73. Immunohistochemical reactions for the validation of some of these results showed negativity for CD44,
RASSF1, and p73.
Conclusion. A loss of copy number of the genes CD44, RASSF1, and TP73 may contribute to the carcinogenesis of CXPAs.
(Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:69-74)Carcinoma ex-pleomorphic adenoma (CXPA) is a rare
malignant tumor that affects the salivary glands and
corresponds to 3.6% of all salivary gland neoplasms
and 11.7% of all salivary malignancies.1,2 CXPA
occurs more commonly in the parotid and submandib-
ular glands but is extremely rare in minor salivary
glands.3 The main site of occurrence of CXPA in the
minor salivary glands is the palate, but involvement
of other locations such as the buccal mucosa, ﬂoor of
the mouth, alveolar ridge, gingiva, retromolar area,
nasopharynx, and upper and lower lips has been
described.4-12
The pathogenesis behind the malignant trans-
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genesis process. A limited group of genes and markers of
PA malignant progression have been described in
previous studies.13-15 Therefore, the objective of this
study was to determine copy number loss in a panel
of tumor suppressor genes using multiplex ligation-
dependent probe ampliﬁcation (MLPA) in a case of
CXPA involving the upper lip. Immunohistochemical
analysis was performed for the validation of MLPA
results as described in the literature.16-18PATIENT AND METHODS
A 69-year-old man was referred for the evaluation of
a nodule on his right upper lip of 4 years duration.
Upon clinical examination, a semiﬁxed ﬁbroelastic
nodular painless lesion on the right side of the upper lip
was observed, measuring approximately 2  2 cm
(Figure 1). With pleomorphic and canalicular adenoma
as the main clinical diagnoses, the lesion was surgically
removed.
Microscopic examination of the surgical specimen
showed an uncapsulated well-circumscribed lesion,
showing intense hyalinization with clusters and nests of
epithelial cells and ductal structures composed of
epithelial and myoepithelial cells (Figure 2A). In some
areas, the epithelial cells were cuboidal, with eosino-
philic cytoplasm and normal nuclei, whereas the ablu-
minal myoepithelial cells were spindle-shaped with
more hyperchromatic nuclei. There was no evident
pleomorphism, cellular atypia, or mitoses (Figure 2B).
These microscopic aspects were suggestive of PA.
Nevertheless, the ducts were larger in other regions
and were formed by pleomorphic cells with increased69
Fig. 1. A and B, Clinical aspects of CXPA involving the upper lip (right side).
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prominent nucleoli (Figure 2C-E). These areas showed
a high immunoexpression of Ki-67 (68.7%) (Figure 2F),
whereas the PA area showed a low proliferative index
(4.8%). The ﬁnal diagnosis was of minimally invasive
CXPA, with a malignant component classiﬁed as
adenocarcinoma not otherwise speciﬁed (NOS).
Clinical and radiographic (chest X-ray) investigations
to detect metastases were negative. Surgical margins
were not satisfactory because the tumor cells were
extending close to the surgical margins, but the patient
declined complementary surgical treatment. After
a follow-up period of 30 months, there was no evidence
of recurrence or metastases.Fig. 2. Carcinoma ex-pleomorphic adenoma of the upper lip. A, Are
of epithelial cells forming typical ductal structures of PA (hema
Epithelial cells forming ducts and presenting mild nuclear pleomorph
invasion showing malignant cells in the adipose tissue surrounding t
of malignant transformation showing large and irregular ducts fo
magniﬁcation 100 and 400). F, High nuclear immunoexpression
original magniﬁcation 400).Tumor DNA was extracted from parafﬁn-embedded
tissue samples using Qiagen extraction kits (Qiagen
GmbH, Hilden, Germany) in accordance with the
manufacturer’s recommendations. The carcinomatous
and benign areas were extracted using a punch with
a 3 mm diameter, but a good concentration and quality of
DNA was obtained only from the malignant area.
To improve the quality of the isolated DNA, an elaborate
extraction protocol speciﬁc for parafﬁn-embedded
tissues was applied, which included thorough depar-
afﬁnization with xylene, methanol washes to remove all
traces of the xylene, and a 24-h incubation period in
1 mol/L sodium thiocyanate to reduce cross-linking.
Subsequently, the tissue pellet was dried and digested fora of PA showing intense hyalinization, with clusters and nests
toxylin and eosin [H&E], original magniﬁcation 100). B,
ism (H&E, original magniﬁcation 400). C, Area of minimal
he lesion (H&E, original magniﬁcation 100). D and E, Areas
rmed by hyperchromatic pleomorphic cells (H&E, original
of Ki-67 in the malignant cells forming a solid island (H&E,
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(ﬁnal concentration: 21 g/1 L, freshly added twice a day).
The MLPA was performed as described in detail
previously using the probe mixture “SALSA MS-
MLPA ME001-C1 tumor suppressor probemix” (MRC-
Holland, Amsterdam, The Netherlands; www.mlpa.
com). The 41 genes, chromosomal regions, and probe
sequences are listed in Table I. This mix was chosen to
enable the analysis of genes that may be involved in
carcinogenesis according to the literature.19,20 Each
probe is composed of two parts that hybridize to adja-
cent target sequences in the DNA. After a ligation step
and PCR ampliﬁcation, each probe gives rise toTable I. SALSA MS-MLPA ME001-“C1 tumor suppr
Netherlands; www.mlpa.com) applied in current case
Genes Chromosomal region Prob
CREM 10p12.1 GCTCCTCCACCAGGTGC
TIMP3 22q12.3 TCCAGCGCCGAGGCAGC
APC 5q22 CTCAGCTGTGTAATCCG
PARK2 6q26 CGTTCACGACCCTCAAC
CDKN2A 9p21 CAGAGGGGAAGAGGAA
MLH1 3p22.1 CGTTGAGCATCTAGACG
TNFRSF1A 12p13 TGCCACACTGCCCTGAG
ATM 11q23 GGAGGGAGGAGGCGAG
RARB 3p24 CCGCCGGCTTGTGCGCT
MLH3 14q24.3 GCGACCTTGTTCTTCCTT
CDKN2B 9p21 CTGCGACAGCTCCTGGA
HIC1 17p13.3 CCGCTCCAGATAAGAGT
PAH 12q23 CAGTGCCCTGGTTCCCA
CHFR 12q24.33 CGCGAGAGTAGGCGCGT
BRCA1 17q21 GTTCTCAGATAACTGGG
CASP8 2q33.2 CTTTCCAATAAAGCATG
CDKN1B 12p13.2 CAGCCCCTGCGCGCTCC
TSC2 16p13.3 GAGCCAGAGAGAGGCTC
PTEN 10q23.3 CACCGGAGCGGGCGCAG
BRCA2 13q12.3 CGGGAGAAGCGTGAGGG
CDK6 7q21.3 GCGTGATTGGACTCCCA
CD44 11p12 CTCCTTTCGCCCGCGCCC
RASSF1 3p21.3 CAGTCCCTGCACCCAGG
CDH1 16q22.1 CTATGAAGGAAGCGGTT
DAPK1 9q22 CGCGAGGATCTGGAGCG
VHL 3p25.3 GCGAAGACTACGGAGGT
AI651963 10p14 CAATTGCCATTTTTTCCT
ESR1 6q25.1 CGCCCGCCGTGTACAAC
RASSF1 3p21.3 GTCCACAGGGCGGGCCC
KLK3 19q13 TGTGTCACCATGTGGGT
TP73 1p36 CGCCCGCGAAGGGGACG
FHIT 3p14.2 CGCGGGTCTGGGTTTCC
BRCA2 13q12.3 GGCCATGGAATCTGCTG
IGSF4 11q23 CCTGGAGCCCGAGTCCT
CDH13 16q24.2 GTTCTGTGCGTTCTCCTG
TNFRSF7 12p13 GAAAGTCCTGTGGAGCC
GSTP1 11q13 CGAAGAGCGGCCGGCGC
MLH1 3p22.1 CTGCTGAGGTGATCTGG
CTNNB1 3p22 GGCTGTTAGTCACTGGC
CASR 3q21 CCAGTGCCTGTAACAAG
*Copy number loss.
yNo ampliﬁcation.a product with a unique size between 136 and 481 nt.
The products from the PCR were subsequently
analyzed on an ABI Prism 3100 sequencer and by
Peak Scanner v1.0 software (Applied Biosystems,
Warrington, UK).
Four normal salivary glands from other patients were
used as reference samples. The normal salivary glands
were harvested due to sialolithiasis or neck dissection
and were histopathologically normal, without inﬂam-
matory alterations or disease. Ratio peak values and the
respective standard deviations were calculated for every
probe. Two steps were performed for the relative copy
number assessment. First, within a sample, the signal ofessor probemix” (MRC-Holland, Amsterdam, The
e sequence Gain/loss P ¼ .05
TACAAT 2.532865 .172682
CTCGC 3.622244 .892368
CTGGATGCGGACC 2.188288 .226996
TTGGCTACT 1.36268 .143438
AGAGGAAGAAGCGCTCAGAT 4.946586 .590262
TTTCCTTGGCTCT 2.245843 .057424
CCCAA 2.672401 .596762
AGGAGTCGGGA 4.118871 .2386
CGCT 0.694583 .067995
TCCTTCCGA 0.488215 .082213
AGCCGG 2.142268 .353573
GTGCGGA 1.224127 .306472
AGAA 0.69783 .104174
GGAGG 1.666117 .405742
CCCCTGC 0.575619 .16082
TCCAGCGCTC 0.093571* .005402*
TAGA 0.42242 .061751
TGAGAAGAAG 0.533916 .158397
GAGA 1.151949 .150278
GACAGATTTGTG 0.578322 .058463
GGAGAAGAAGACT 0.389723 .105289
TCC 0.154174* .027022*
TTTCCA 0.164012* .019109*
CCGAAGCTGCTA 0.175978* .046324*
AACTGCT 0.166015* .018447*
CGACTCGGG 0.230296 .093986
GACATTCACTGT 0y 0y
TACCCCG 0.077711* .013292*
CGAC 0.072722* .005532*
CCCG 0y 0y
CAGC 0.071952* .004428*
ACGC 0y 0y
AACAAAA 0y 0y
TGCACGCCA 0y 0y
TCCCAG 0y 0y
TGCA 0y 0y
CGTG 0y 0y
CGCAGA 0y 0y
AGCAACA 0y 0y
TGCCCAGATGACT 0y 0y
Table II. Immunohistochemical ﬁndings for validation
of multiplex reaction
Antibody Source, clone Dilution
Result
PA* CXPA*
RASSF1 eBioscience, eB114-10H1 1:500 þ 
CD44 Novocastra, F10-44-2 1:40  
CDH1/E-cadherin Dako, NCH-384 1:200 þ þ
DAPK1 Sigma, DAPK-55 1:600 þ þ
p73 Abcam, EP436Y 1:100  
bcl-2 Dako, 124 1:50  
ESR1 Dako, 1D5 1:35  
CASP8 Novocastra, 11B6 1:50 þ þ
*Ductal epithelial cells from pleomorphic adenoma (PA) and carci-
noma ex-pleomorphic adenoma (CXPA).
ORAL AND MAXILLOFACIAL PATHOLOGY OOOO
72 Mariano et al. July 2013each probe was divided by the signal of every reference
probe (intrasample normalization). Second, the peak
pattern of the sample of interest was compared with that
obtained for reference samples that were included in the
same experiment (intersample normalization). The ﬁnal
probe ratio obtained from the two normalizations was
then used to determine the ploidy status of the analyzed
region. MLPA experiments analyzing reference
samples should normally result in signal ratios varying
between 0.85 and 1.15, including the standard devia-
tion, for each probe. Therefore, it was determined that
ratio values, including the standard deviation, lower
than 0.7 should be interpreted as losses and ratios
higher than 1.3 as gains at the target sites under
investigation. This interpretation of MLPA data is in
accordance with Moerland et al.,21 who found a 98%
concordance with data obtained by ﬂuorescence in situ
hybridization spot counting, both performed on parafﬁn
tumor material. P values <.05 were considered signif-
icant. P values in MLPA represent probes with indi-
vidual standard deviations lower than 0.05 as abnormal,
despite the overall oscillation.
The alterations detected in the current case included
loss of CASP8 (2q33.2), CD44 (11p12), CDH1
(16q22.1), DAPK1 (9q22), ESR1 (6q25.1), RASSF1
(3p21.3), and TP73 (1p36). A summary of the ﬁndings
is shown in Table I. The genes AI651963, KLK3, FHIT,
BRCA2, IGSF4, CDH13, TNFRSF7, GSTP1, MLH1,
CTNNB1, and CASR were not ampliﬁed.
A validation of the genetic studies was performed
using the following primary antibodies: CASP8, CD44,
CDH1, DAPK1, ESR1, RASSF1, and p73 (Table II).
EnVision plus (4001; Dako) was the detection system,
and DAB (Sigma) was used as the chromogen. Cells
were considered positive when the cytoplasm (CASP8
and DAPK1), cell membrane (CD44, CDH1, and
RASSF1), and nuclei (ESR1, p73) stained brown.
Areas for PA and CXPA showed similar immunohis-
tochemical results, except for RASSF1, which was
positive in PA and negative in CXPA areas (Table II).
Normal salivary glands show immunoexpression with
the markers, except ESR1 antibody. Positive controls
for each of the antibodies are noted in parentheses:
CASP8 (intestine), CD44 (tonsil), CDH1 (intestine),
DAPK1 (intestine), ESR1 (breast), RASSF1 (squamous
epithelial cells from oral mucosa), and p73 (tonsil).DISCUSSION
Typically, CXPA of the minor salivary gland is poorly
circumscribed and inﬁltrative, measuring about 2 cm, as
in the current case. Histological diagnosis of CXPA can
be a challenge, especially if the sample is small, as
frequently occurs in oral tumors. CXPA should be clas-
siﬁed according to its invasiveness and histopathologicalsubtypes; the present case was considered a minimally
invasive adenocarcinoma NOS.
A wide surgical excision with adequate margins is
the basic treatment for malignant minor salivary gland
tumors, and postoperative radiotherapy and chemo-
therapy can also be used.3 Minimally invasive CXPA is
usually only treated by surgery. The present case, after
a follow-up of 30 months, did not present any evidence
of recurrence or metastasis.
The transformation of a PA to a CXPA requires
multiple genetic alterations, which are not yet well
deﬁned. Alterations of the cellular cycle, which are
associated with the inactivation of tumor suppressor
genes including P16, TP53, RASSF1, RB, hTERT,WT1,
and K-ras, seem to be important for CXPA carcino-
genesis.13-15 The current case showed alterations of
eight tumor suppressor genes: CASP8 (2q33.2), CD44
(11p12), CDH1 (16q22.1), DAPK1 (9q22), ESR1
(6q25.1), RASSF1 (3p21.3), and TP73 (1p36).
The CASP8 gene encodes a member of the cysteinee
aspartic acid protease (caspase) family, which has
a function in apoptosis. The CASP8 gene prevents
hyperproliferation and tumorigenesis, and this essential
role was described in head and neck carcinoma cells.22
However, there have been no studies of the CASP8
gene and caspase8 protein in CXPA carcinogenesis.
A loss of copy number of the CASP8 gene was found in
this patient; however, strong immunohistochemical
expression was also found, indicating that there are
other pathways available for protein production. In
addition, there may be other genomic phenomena that
inﬂuence cancer risk, e.g., polymorphisms.23
The CD44 gene encodes a cell surface glycoprotein
that is involved in communication between cells, in cell
adhesion and migration.24 The expression of CD44
protein was investigated by Yang et al.,24 and the
authors concluded that decrease of CD44 expression
promoted recurrence and carcinogenesis of CXPA.
Franchi et al.25 found that loss of CD44v3 and CD44v6
proteins was associated with the onset of CXPA and
OOOO CASE REPORT
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uting to the development of distant metastases. These
ﬁndings support loss of CD44 as a malignancy-
associated alteration, which was validated by the
immunohistochemical reaction. The PA area also
showed negativity for CD44 protein.
The CDH1 gene encodes a cadherin superfamily
protein. Mutations in this gene are associated with
several types of cancer. A loss of function contributes to
progression in cancer by increasing proliferation, inva-
sion, and/or metastasis.26 There are no studies of the
CDH1 gene in the carcinogenesis of CXPA. CDH1 gene
mutations have led to increase of E-cadherin immu-
noexpression.27 Immunoexpression for E-cadherin in
PA and CXPA areas of the tumor was observed.
The DAPK1 (death-associated protein kinase 1) gene
encodes a protein that is a positive mediator of
g-interferon-induced programmed cell death, auto-
phagy, and tumor invasion.28,29 Even with copy
number losses of this gene, the immunohistochemical
reaction showed protein expression. However, the
methylation of this gene, as with the ESR1 gene, is
associated with the progression of head and neck
squamous cell carcinoma.19 The ESR1 gene encodes an
estrogen receptor that is important for hormone binding,
DNA binding, and the activation of transcription.19
Even having copy number losses of the ESR1 gene and
immunoexpression negativity, as in the current case,
this gene and its protein, perhaps, has low or absence of
expression in normal salivary gland cells. Estrogen acts
through its two receptors, ESR1 (or ER-a) and ESR2
(or ER-b).30 ESR1 is the dominant receptor in the adult
uterus. On the other hand, ESR2 is expressed at high
levels in other estrogen-target tissues such as prostate,
salivary glands, ovary, vascular endothelium, smooth
muscle, nervous system, and the immune system.30,31
In these last tissues, which depend on estradiol for
maintenance of structure, function, or both, estrogenic
signals are mediated by ESR2 and not ESR1.30
The RASSF1 gene encodes the Ras-association
domain-containing protein 1. The altered expression or
loss of this gene has been associated with the carcino-
genesis process. This protein inhibits the accumulation
of cyclin D1 and thus induces cell cycle arrest. Schache
et al.15 determined that the RASSF1 gene was the single
gene promoter for which methylation is shown to be
a statistically signiﬁcant predictor of CXPA. Copy
number losses were detected in this case, and negativity
for the immunomarker was seen in CXPA. The PA
component showed immunoexpression, indicating that
it had a function in CXPA carcinogenesis but not in PA
tumorigenesis.
The TP73 gene encodes a member of the p53
family of transcription factors, which are involved
in cellular responses to stress and development.The overexpression of TP73 promotes growth arrest
and/or apoptosis. This gene may be deleted in various
human cancers,32 but nothing has been published about
its possible role in CXPA. The current ﬁndings are in
accordance with the literature because a copy number
loss was detected, which was conﬁrmed by the absence
of immunoexpression.
The MLPA reaction showed a number of tumor
suppressor genes with higher copy numbers in the
tumor, which can be considered an artifact. The artifacts
can be present in MLPA reaction, mainly in formalin
ﬁxed parafﬁn-embedded tissue. The most common type
of artifact is contaminant from fragmented DNA. Many
factors can affect the MLPA results, such as artifacts
formed during the experimental procedure or poly-
morphisms/mutations in the probe target sequence.
Despite the overall oscillation, only probes with indi-
vidual standard deviations lower than 0.05 were
considered abnormal.
The three genes (CASP8, CDH1, and DAPK1)
identiﬁed as downregulated by MLPA showed immu-
nohistochemical positivity indicating detection of
the corresponding proteins. This discrepancy may
reﬂect the complexity of the mechanisms governing
messenger RNA expression and protein production, as
well as the lack of speciﬁcity of the MLPA and
immunohistochemical techniques.
In summary, this case illustrates that alterations of
genes, including CD44, RASSF1, and P73, with the loss
of copies detected by MLPA can contribute to CXPA
carcinogenesis. To complement our ﬁndings, future
investigations of a larger scale employing other tech-
niques should be performed.REFERENCES
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